Login
$IMUX
$7.23 -$0.29 (3.86%) Live

$IMUX 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Results of Operations and Financial Condition

– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 –

05 Nov 2026 8-K: Regulation FD Disclosure

On November 5, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “PMS R&D Day”). The PMS R&D Day will take place on Thursday, November 5, 2026, fr...

11 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the “Company”). Dr. Nash’s resignation was not the result of any disagreement with the Company o...

09 Sep 2026 8-K: Regulation FD Disclosure

On September 9, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar (the “RMS R&D Day”). The RMS R&D Day will take place on Wednesday, September 9, 2026, f...

11 Aug 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –

14 Jul 2026 8-K: Regulation FD Disclosure

On July 14, 2026, Immunic, Inc. a Delaware corporation (the “Company” or “Immunic”) made available an updated presentation (the “Presentation”) on the Company's website.

06 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 29, 2026, Tamar Howson resigned as a member of the Compensation Committee of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the “Company”), and as a member of the Board, as Ms. Howson transitions i...

29 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

1.1 Effective Date of the Plan. The Board of Directors of Immunic, Inc., a Delaware corporation (the “Company”), adopted this 2019 Omnibus Equity Incentive Plan (the “Plan”) effective as of June 14, 2019 (the “Effective Date”), as amende...

28 May 2026 8-K: Regulation FD Disclosure

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

27 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Employment Agreement (the “Agreement”) dated as of May 22, 2026 (the “Effective Date”), is being entered into by and between IMMUNIC, INC., a Delaware corporation (the “Company”), and Erik Lundgren (the “Executive”).

19 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –

13 May 2026 8-K: Results of Operations and Financial Condition

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –

28 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Employment Agreement (the “Agreement”) dated as of April 23, 2026 (the “Effective Date”), is being entered into by and between IMMUNIC, INC., a Delaware corporation (the “Company”), and Michael Panzara (the “Executive”).

23 Apr 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

NEW YORK, April 23, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the “Company” or “Immunic”), today announced that it will effect a re...

14 Apr 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

On April 14, 2026, Immunic, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders voted on one proposal, which is described in more detail in the Company’s...

10 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Retention Bonus Agreement (this “Agreement”), dated as of April 7, 2026 (the “Effective Date”), is being entered into by and between DANIEL VITT (the “Executive”) and IMMUNIC, INC., a Delaware corporation, (the “Company”) (each a “P...

01 Apr 2026 8-K: Other Events

NEW YORK, April 1, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the “Notice”) from th...

31 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –

26 Feb 2026 8-K: Results of Operations and Financial Condition

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –

13 Feb 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This PURCHASE AND SALE AGREEMENT, dated as of February [12], 2026 (this “Agreement”), is made and entered into by and among Immunic, Inc., a Delaware corporation (the “Seller”), each of the entities listed on Exhibit A hereto (each, a “B...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support